Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -2.70% 18.00p 17.00p 19.00p 18.50p 18.00p 18.50p 65,191.00 14:40:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.0 -4.2 - 37.50

Amryt Pharma (AMYT) Latest News

More Amryt Pharma News
Amryt Pharma Takeover Rumours

Amryt Pharma (AMYT) Share Charts

1 Year Amryt Pharma Chart

1 Year Amryt Pharma Chart

1 Month Amryt Pharma Chart

1 Month Amryt Pharma Chart

Intraday Amryt Pharma Chart

Intraday Amryt Pharma Chart

Amryt Pharma (AMYT) Discussions and Chat

Amryt Pharma Forums and Chat

Date Time Title Posts
22/2/201712:04Amryt Pharma843.00
13/6/201610:19Amryt Pharma102.00
21/4/201609:04Amryt Pharma2.00

Add a New Thread

Amryt Pharma (AMYT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
27/02/2017 15:28:2017.601,477259.95O
27/02/2017 14:49:0417.131,912327.53O
27/02/2017 14:48:4417.609,5001,672.00O
27/02/2017 14:40:2917.505,000875.00O
27/02/2017 12:01:3517.675,629994.64O
View all Amryt Pharma trades in real-time

Amryt Pharma (AMYT) Top Chat Posts

Amryt Pharma Daily Update: Amryt Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AMYT. The last closing price for Amryt Pharma was 18.50p.
Amryt Pharma has a 4 week average price of 18.29p and a 12 week average price of 18.79p.
The 1 year high share price is 25p while the 1 year low share price is currently 13.75p.
There are currently 208,339,631 shares in issue and the average daily traded volume is 72,791 shares. The market capitalisation of Amryt Pharma is £37,501,133.58.
buffythebuffoon: Friel leaves, share price goes up. Come on JP..a golden opportunity... Buffy
icebreaker: For me the only real interest in this RNS is the fact that P3 is still going ahead in this quarter (late Q1); this being the only short term share price driver that I am aware of. I think they will deliver a further RNS on this now that they have confirmed it. Hopefully this week.
cpap man: Dear Proactive Investor For the second working day in a row, Amryt’s boss Joe Wiley has been in the Proactive Investors office with some terrific news. Today’s news, about a licensing deal for a drug that treats a horrible cholesterol condition, was even more of a blockbuster than last Friday’s funding deal, and sent the share price soaring to 20p from 16.5p overnight, though some of the profits had been creamed off by the close. In our lead item, Ian Lyall explains the significance of the deal, which will not cost the company any money but which will provide it with a means of generating cash. In our Stocktube section, Wiley himself tells our presenter Charlotte Kan a little bit more about the disease the drug treats and what the licensing deal entails. ETC....
buffythebuffoon: No JP, stop anchoring on a share price! This is a biopharma that will multibag with any degree of success. The daily movements in the share price are meaningless for investors who bought in having read and understood the business case. Those who passively sat there when AMRYT reversed into Fastnet, without actively looking at the business, need to recognise that they must look to themselves as the problem, not others. After all, instead of doing the square root of zero, they could have sold. Buffy
currypasty: ''We had the opportunity to do an equity raise but we believed that relative to the opportunity that Amryt represents, that our share price is materially undervalued right now, we felt therefore that doing an equity raise, which would be dilutive to shareholders, would be the wrong strategy.''
papillon: It's proving to be a very slow death for the AMYT share price in the continuing absence of good news (in fact any news!) from the company. I seem to remember the intraday low was around 14-14.25p back in early July. Will a retest of that low encourage bottom fishing buyers again, or will the AMYT share price continue it's descent into oblivion? Answers on a postcard please! LOL. Is AMYT worth a bottom fishing buy I wonder when it's below 15p?
gnnmartin: I went to the meeting. Yes they will need to raise money sometime. I think they said they have enough cash to last them to June '18. Only think, because it looks to me as though they will be running tight by Jan 2018. They think they should be able to raise money by (for example) selling the rights to Episalvan in Japan for the treatment of Epidermolysis Bullosa (EB) for an up front plus milestones plus royalty. I expect that they hope the share price might get nearer where they think it should be, then perhaps they would raise cash on the market. That's my assessment, I'm not reporting what was said. Anyhow, sufficient unto the day. I was impressed by the presentation. I was sorry that Tim was not there to ask more informed questions. One question that had troubled me was whether Episalvan would sell for the same price when treating EB as it does for treating partial wounds, and the answer was yes: the extra revenues come because the daily use by EB sufferers will be many times greater than a partial thickness wounds. I came away impressed, happy to hold.
papillon: dingo75 16 Aug'16 - 13:26 - 295 of 302 1 0 papp lol egg on your FACE! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. I'm always ending up with egg on my face, dingo75. However I still believe we will see a small, short term, fall back in the AMYT share price and then the formation of a bullish Inverse Head & Shoulders. You could be right and I will be proved wrong and end up with egg on my face, but I'm hopeful I will soon be proved right. After all a bullish chart formation, after a period of a falling share price, is often the sign that a significant price reversal and subsequent major share price rise is on the cards. Don't throw any more raw eggs at me just yet, dingo75, but keep them ready! LOL.
jacksonpollack: Point is it wasn't a dog and sound share price is flying up over 150% in past 3 weeks. Once the full extent of the gas find comes out the sky is the limit regarding their share price fastnet knew what was there and had the data to back it up. They just took the decision not to carry on with it. Shame as look where we are today, over 40% down on rip off consolidation share price and miles away from share price when we had Tendrara.
papillon: Amryt Pharmaceuticals is worth a closer look By Gary Newman | Sunday 1 May 2016 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article. As usual I had a great day at the UK Investor Show, especially listening to many of the informative speakers on the main stage. When it came to the companies exhibiting, to be honest there are many of them which I wouldn’t dream of putting my money into – either because I view them as poorly run or vastly over-valued at their current share prices. But there were also some that look to have good potential for the future, as well as offering value, and are definitely on my watch list, and amongst them was recently listed Amryt Pharmaceuticals (AMYT) which completed a reverse takeover into Fastnet Equity and was admitted to trading a couple of weeks ago. I previously covered this company as a buy at 2.9p one weekend back in late February, but it was then suspended before open on the Monday morning when news of the deal was confirmed, and you can now get in even cheaper as the opening day price of 24p (equivalent to 3p prior to the deal) has subsequently dropped to under 20p to buy. It is still early days and like any similar stage pharmaceutical company it does carry a fair amount of risk, but unlike many of the AIM listed ones it does at least have a product, Episalvan, that is already approved in the EU, Norway and Iceland, and also has further potential for development to treat other diseases. Amryt has a very short history as it was only formed in August of last year, but that came about via the acquisitions of German bio-tech Birken AG and Swiss pharmaceuticals company Sompharmaceuticals SA. It also has a team behind it that have a good track record in the industry, with chairman Harry Stratford having previously built two successful listed pharma companies (including Shire which is now FTSE100 listed), and CEO Joe Wiley and CFO/COO Rory Nealon who have years of experience in life sciences. Its licenced product Episalvan is used to treat partial-thickness wounds in adults, but the company is looking to extend that to epidermolysis bullosa, which commonly occurs in children, and is expecting to begin phase three trials in the second half of this year. The company currently has orphan status in both the US and EU for this potential EB treatment, meaning that not only will it get tax breaks but also an exclusivity period to develop a cure for this condition. The only downside with that is that orphan drugs tend to be less profitable than those that cure common illnesses, but can still be very lucrative and the global EB market is estimated at $1.5 billion per annum, so the company won’t even need a big slice of that to succeed. Amryt also has the Imlan brand (developed by Birken) which is on sale and is used by people suffering from dry skin and other dermatitis conditions. There are also a couple of other drugs, but they are yet to undergo clinical trials and are too early a stage to really be that relevant at the moment, although that could well change in the future. In terms of the financials it is very hard to get a real grip on these as there isn’t a lot to go on by way of figures, other than that the company raised a gross amount of £10 million at 24p when it listed in April, and prior to that it also had close to £10 million in the bank. The total amount paid for the takeover of Amryt was just under £30 million in shares and was settled by the issue of 123 million shares (circa 59%) in the new company, with those who originally sold Birken receiving 30 million of those, and 12 million going to former Som owners. Since relisting it should have paid Birken €10 million as a milestone payment for the Episalvan EU approval, with potentially a further €40 million to pay in the future, plus royalties on this product of 6-9% of sales for a ten year period. For a company of this size there is a relatively small freefloat, with over 62% of shares not in public hands, and the Software AG-Stiftung fund owning 20.9%, and previously having funded Birken to the tune of around €54 million to develop its products. There is too much to go into every detail, so I would suggest that anyone interested in investing reads the admission document before doing so, and also realises that this does still have risks attached if it is going to justify its current market cap of £42 million. But I think the current share price, or possibly even slightly lower if you get he chance, offers a good buying opportunity as I think many people piled into this one expecting fireworks overnight. But typically of many PIs, when that didn’t happen they have gradually got bored and sold to chase riches elsewhere, and that has dragged the share price down to where it is. That unfortunately is also one of the disadvantages of a small freefloat as it doesn’t take a lot of selling to have a disproportionate affect on the share price, but that also works the other way at times when the shares are in high demand, such as after good news. So for me overall this is a speculative buy at these levels, especially given how far along the road it is with its products compared to many similar sized pharmas. Just be aware that it will need to raise further funding in the future, although that might not need to be via equity issue given previous funding from the biggest shareholder. - See more at: HTTP://
Amryt Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170228 01:03:10